Editas Medicine Inc (EDIT)

NASDAQ HEALTHCARE
$3.26 -1.21% RSI 55 Neutral Add Alert

Moving Averages

SMA 200
$2.70
Price above

Company Profile

Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.

Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Market Cap
$500.29M
P/E Ratio
None
EPS
$-1.14
Beta
2.1
Dividend Yield
0.00%
52-Week High
$4.537
52-Week Low
$1.66

Similar stocks in BIOTECHNOLOGY

BNTX
BioNTech SE
RSI 44.0
VRTX
Vertex Pharmaceuticals Inc
RSI 51.0
CRSP
CRISPR Therapeutics AG
RSI 41.0
MRNA
Moderna Inc
RSI 55.0
VKTX
Viking Therapeutics Inc
RSI 59.0
SRPT
Sarepta Therapeutics Inc
RSI 56.0
IOVA
Iovance Biotherapeutics Inc
RSI 53.0
NVAX
Novavax Inc
RSI 51.0
DNA
Ginkgo Bioworks Holdings Inc - Class A
RSI 49.0
RXRX
Recursion Pharmaceuticals Inc - Class A
RSI 52.0

Data last updated: July 13, 2026 at 1:30 AM EDT

Track EDIT for free

Get e-mail RSI alerts when Editas Medicine Inc enters oversold or overbought territory. Free forever.

Add Alert